Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Vaccine

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0264-410X(92)90068-UPMID 1534641
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Safety and Immunogenicity of a Human Immunodeficiency Virus Type 1 (HIV-1) Recombinant gp160 Candidate Vaccine in Humans

  1991cited by this paper
• The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.

  1991cited by this paper
• Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients.

  1991cited by this paper
• Lymphoproliferative Responses to Mitogens and HIV-1 Envelope Glycoprotein Among Volunteers Vaccinated with Recombinant gp160

  1990cited by this paper
• Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine.

  1990cited by this paper
• Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals

  1989cited by this paper
• Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

  1989cited by this paper
• Type-restricted neutralization of molecular clones of human immunodeficiency virus.

  1988cited by this paper
• An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes.

  1988cited by this paper
• Modulation by immunosuppressive agents of peripheral blood mononuclear cell responses to influenza A virus.

  1987cited by this paper
• Modulation by immunosuppressive agents of peripheral blood mononuclear cell responses to influenza A virus.

  1987cited by this paper
• Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion.

  1987cited by this paper
• Expression of AIDS virus envelope gene in recombinant vaccinia viruses

  1986cited by this paper
• Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone

  1986cited by this paper
• Nucleotide sequence of the AIDS virus, LAV.

  1985cited by this paper
• Cell-mediated immune response of human lymphocytes to influenza A/USSR (H1N1) virus infection

  1980cited by this paper
• Selected Methods in Cellular Immunology

  1980cited by this paper
• Isolation of mononuclear cells and granulocytes from human blood.

  1968cited by this paper
• Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

  1968cited by this paper

• Recombinant protein vaccines produced in insect cells

  2012cites this paper
• Vaccines for Human Immunodeficiency Virus-1 Infection

  2010cites this paper
• Cellular Immune Responses in Asymptomatic Human Immunodeficiency Virus Type 1 (HIV-1) Infection and Effects of Vaccination with Recombinant Envelope Glycoprotein of HIV-1

  2006cites this paper
• Vaccines for Viral and Parasitic Diseases Produced with Baculovirus Vectors

  2006cites this paper
• Chapter 39 – Progress in the Development and Testing of HIV Vaccines

  2004cites this paper
• A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.

  2001cites this paper
• Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.

  2001cites this paper
• Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120.

  2001cites this paper
• HIV Type 1 Vaccine-Induced T Cell Memory and Cytotoxic T Lymphocyte Responses in HIV Type 1-Uninfected Volunteers

  2001cites this paper
• HIV vaccines for prevention of infection and disease in humans.

  2000cites this paper
• Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response.

  1999cites this paper
• HIV-1MN Recombinant Glycoprotein 160 Vaccine-Induced Cellular and Humoral Immunity Boosted by HIV-1MN Recombinant Glycoprotein 120 Vaccine

  1999cites this paper
• Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls.

  1999cites this paper
• Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies.

  1999cites this paper
• Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

  1998cites this paper
• Induction of specific T‐cell responses in HIV infection

  1998cites this paper
• Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group

  1996cites this paper
• A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

  1996cites this paper
• Safety and Immunogenicity of Env 2-3, a Human Immunodeficiency Virus Type 1 Candidate Vaccine, in Combination with a Novel Adjuvant, MTP-PE/MF59

  1996cites this paper
• A Dose-Ranging Study of a Prototype Synthetic HIV-1MN V3 Branched Peptide Vaccine

  1996cites this paper
• T-Cell Epitopes of HIV-1 Envelope Glycoprotein

  1996cites this paper
• Human studies in the development of human immunodeficiency virus vaccines.

  1995cites this paper
• HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network.

  1995cites this paper
• Phase I/II Preventive Vaccine Trials: Conference Summary

  1995cites this paper
• Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network.

  1995cites this paper
• Studies of High Doses of a Human Immunodeficiency Virus Type 1 Recombinant Glycoprotein 160 Candidate Vaccine in HIV Type 1-Seronegative Humans

  1994cites this paper
• The use of the clinical immunology laboratory

  1994cites this paper
• Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.

  1994cites this paper
• Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160.

  1994cites this paper
• Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.

  1994cites this paper
• Genetically Engineered Human Immunodeficiency Virus Type 1 (HIV-1) Vaccines

  1994cites this paper
• Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.

  1994cites this paper
• Neutralizing Antibodies to HIV-1 in Seronegative Volunteers Immunized With Recombinant gp 120 From the MN Strain of HIV-1

  1994cites this paper
• HIV‐1 recombinant gp160 vaccine given in accelerated dose schedules

  1994cites this paper
• Efficacy trials of AIDS vaccines: how science can inform ethics.

  1994cites this paper
• Potential pitfalls on the road to an effective HIV vaccine.

  1994cites this paper
• Challenges and strategies for AIDS vaccine development.

  1993cites this paper
• Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine.

  1993cites this paper
• Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

  1993cites this paper
• Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.

  1993cites this paper
• Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection.

  1993cites this paper
• Human trials of experimental AIDS vaccines.

  1993cites this paper